Sangamo Therapeutics Secures $150 Million in Fundraising to Revolutionize Gene-based Medicine

RAPT Therapeutics is thrilled to announce a monumental funding achievement, having successfully raised $150 million to further its mission of revolutionizing the treatment landscape for patients with serious genetic diseases. This significant capital infusion is a testament to the strength of our innovative gene-based therapeutic development technologies and the profound impact they can have on patient lives. As pioneers in the field, our expert scientists are leading the charge in groundbreaking research that includes the very first in vivo human genome editing studies. These critical clinical trials are poised to unlock new possibilities in treating genetic disorders, allowing us to push the boundaries of medical science further than ever before. The funding will be instrumental in accelerating our ongoing research initiatives and expanding our clinical pipelines, bringing us closer to developing transformative therapies that address the unmet needs of patients globally. At RAPT Therapeutics, we believe in the power of science to create a brighter future for those suffering from debilitating conditions, and with this funding, we are now better equipped to turn that belief into reality. To learn more about our pioneering work and how we’re changing lives through advanced genetic research, visit our website at www.sangamo.com. We are excited about what lies ahead and are grateful to our investors for their confidence in our vision and capabilities. Together, we are one step closer to realizing the potential of gene-based therapies and bringing hope to countless patients.